{"url_path":"/sec/cai/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/2019410/0002019410-26-000046-index.html","accession_number":"0002019410-26-000046","cik":"0002019410","ticker":"CAI","issuer_name":"Caris Life Sciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2019410/0002019410-26-000046-index.html","primary_entity_key":"0002019410","primary_entity_name":"Caris Life Sciences, Inc."},"word_count":371,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders.\n\nCaris Life Sciences, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders on June 4, 2026 (the “2026 Annual Meeting”). The Company’s shareholders were asked to vote on two proposals, each as more fully described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 23, 2026: (1) to elect ten director nominees to the Board to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified or their earlier death, resignation, disqualification or removal; and (2) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nAs of the close of business on the record date of April 9, 2026, there were 282,662,545 shares of the Company’s common stock issued, outstanding and eligible to vote if represented in person or by proxy at the 2026 Annual Meeting. A total of 273,714,520 shares were represented at the 2026 Annual Meeting, which constituted a quorum.\n\nThe shareholder voting results by proposal are set forth in the tables below:\n\nProposal No. 1: Election of Directors\n\nEach of the following director nominees was elected to serve for a term expiring at the 2027 Annual Meeting by the votes set forth in the table below.\n\nNameVotes ForVotes WithheldBroker Non-Votes\n\nDavid Dean Halbert216,983,42445,644,07011,087,026\n\nBrian J. Brille216,953,60745,673,88711,087,026\n\nPeter M. Castleman200,435,90962,191,58511,087,026\n\nDavid Fredrickson228,579,06134,048,43311,087,026\n\nJoseph E. Gilliam215,798,27946,829,21511,087,026\n\nJon S. Halbert215,600,78747,026,70711,087,026\n\nLaura I. Johansen227,201,42135,426,07311,087,026\n\nDr. Lloyd B. Minor228,662,42533,965,06911,087,026\n\nDanny Phillips214,817,15347,810,34111,087,026\n\nDr. Jeffrey Vacirca228,673,48433,954,01011,087,026\n\nProposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the shareholders by the votes set forth in the table below.\n\nVotes ForVotes AgainstAbstentions\n\n273,517,32460,882136,314\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 5, 2026\n\nCARIS LIFE SCIENCES, INC.\n\nBy:/s/ Luke Power\n\nName:Luke Power\n\nTitle:Senior Vice President, Chief Financial Officer and Chief Accounting Officer"}